Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimer's Vaccine in 19...(ensure that the antibodies generated do ...)

Date:9/19/2007

ensure that the antibodies generated do not interfere with the normal physiological functions of the Amyloid Precursor Protein. RECALL-VAX(TM) is specifically designed to address these issues." Professor Benjamin Chain is the brother of Intellect's Chairman and CEO, Dr. Daniel Chain.

About the RECALL-VAX(TM) technology:

The key to inactivation of amyloid-beta toxin by vaccination is to stimulate a strong antibody immune response that targets and inactivates or promotes the clearance of the toxin. The generation of such antibodies requires a T-cell response. Although beta amyloid contains epitopes that can stimulate such a T-cell response, these particular epitopes carry the risk of inducing harmful autoimmunity. In RECALL-VAX(TM), the harmful human beta amyloid specific T-cell epitopes are replaced with a safe T-cell epitope, such as bacterial Tetanus Toxoid, against which most people have been vaccinated. Moreover, by using only short fragments of the amyloid-beta toxin too small to contain T-cell epitopes, the immune response is more specific than when larger pieces are used, ensuring that only the toxin, rather than the Amyloid Precursor Protein, is targeted by the antibody.

About Alzheimer's disease

Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are over 12 million people suffering from Alzheimer's disease in the major markets worldwide with the number increasing as the global population ages. Currently marketed drugs transiently affect some of t
'/>"/>

SOURCE Intellect Neurosciences, Inc. Copyright©2007 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related biology technology :

1. Inline intellectual property raises legal issues
2. Intellectual Property: Are you an infringer?
3. Starting a tech business? Step 1 is minding the intellectual property
4. Protect your intellectual property before its too late
5. Protecting your intellectual property in overseas markets
6. Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine in Bovine Plasma using the TSQ Quantum Mass Spectrometer
7. Correlation of Bio-Plex Suspension Array Reader Validation With Multiplex Cytokine Assay Performance, Rev A
8. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
9. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
10. Mirus granted European patent for gene therapy
11. Info security group announces first Eastern European chapter